DavidRobertNelsonMD

PubMed

• 118 citations
  Genetic demixing and evolution in linear stepping stone models
  Kirill S. Korolev, Mikkel Avlund, Oskar Hallatschek, David R. Nelson
  Reviews of Modern Physics. 2010-05-21
• 441 citations
  Genetic drift at expanding frontiers promotes gene segregation
  Oskar Hallatschek, Pascal Hersen, Sharad Ramanathan, David R. Nelson
  Proceedings of the National Academy of Sciences of the United States of America. 2007-12-11
• 39 citations
  CD8+ T-cell interaction with HCV replicon cells: evidence for both cytokine- and cell-mediated antiviral activity.
  Chen Liu, Haizhen Zhu, Zhengkun Tu, Yiling Xu, David R. Nelson
  Hepatology. 2003-06-01

Journal Articles

• Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Chronic Hepatitis C Patients in the U.S.  
  David Nelson, MD, Hepatology
• A Comprehensive Assessment of Patient Reported Symptom Burden, Medical Comorbidities, and Functional Well Being in Patients Initiating Direct Acting Antiviral Therapy ...  
  Souvik Sarkar, Michael W. Fried, Richard K. Sterling, Paul W. Stewart, Nancy Reau, Joseph K. Lim, David R. Nelson, Marina Serper, PLoS One
• Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015  
  Kasting ML, Giuliano AR, Reich RR, Roetzheim RG, Nelson DR, Shenkman E, Vadaparampil ST, Cancer Epidemiol Biomarkers Prev, 1/1/2018
• Open-label study to evaluate the safety and tolerability of Telaprevir in combination with Sofosbuvir in naive subjects with HCV genotype 1  
  Morelli G, Firpi R, Horne P, Peter J, Vainorious V, George S, De La Roda A, Fried M, Nelson DR, J Gastroenterol Hep Res, 1/1/2015
• Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens  
  Younossi ZM, Stepanova M, Nader F, Jacobson IM, Gane E, Nelson D, Lawitz E, Hunt SL, Hepatol, 1/1/2014
• VX-222, a non-nucleoside NS5B polymerase inhibitor in telaprevir-based regimens for genotype 1 hepatitis C virus infection  
  Di Bisceglie AM, Sulkowski M, Gane E, Jacobson IM, Nelson D, DeSouza C, Alves K, George S, Kieffer T, Zhang E, Kauuman R, Asmal A, Koziel MJ, Eu J Gastroenterol Hepatol, 1/1/2014
• Clinical pharmacogenetics implementation: Approaches, successes, and challenges  
  Weitzel KW, Elsey AR, Langaee TY, Burkley B, Nessl DR, Obeng AO, Staley BJ, Dong HJ, Allan RW, Liu JF, Cooper-Dehoff RM, Anderson RD, Conlon M, Clare-Salzler MJ, Nelso..., Am J Med Genet C Semin Med Genet, 1/1/2014
• Efficacious versus effective: what�s in an adjective?  
  Lampotang SS, Nelson DR, Hamstra SJ, Naik V, Simul Healthc, 1/1/2013
• Serum levels of soluble CD25 as a marker for hepatocellular carcinoma  
  Cabrera R, Fitian AI, Ararat M, Xu Y, Brusko T, Wasserfall C, Atkinson MA, Liu C, Nelson DR, Oncol Lett, 1/1/2012
• Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS)  
  Shamoon H, Center D, Davis P, Tuchman M, Ginsberg H, Califf R, Stephens D, Mellman T, Verbalis J, Nadler L, Shekhar A, Ford D, Rizza R, Shaker R, Brady K, Murphy B, Cr..., Clin Transl Sci, 1/1/2012
• Is MELD associated with quality of life after liver transplantation?  
  Rodrigue JR, Nelson DR, Reed AI, Hanto DW, Curry MP, Prog Transplant, 1/1/2011
• Racial differences in hepatitis C treatment eligibility  
  Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Novie..., Hepatology, 1/1/2011
• Boceprevir for untreated chronic HCV genotype 1 infection  
  Poordad F, McCone J, Bacon BR, et al, SPRINT-2 Investigators, N Engl J Med, 1/1/2011
• The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma  
  Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, Morelli G, Clark V, Suman A, George TJ, Nelson DR, Aliment Pharmacol Ther, 1/1/2011
• Hepatitis B reactivation and rituximab in the oncology practice  
  Villadolid J, LaPlant KD, Markham MJ, Nelson DR, George TJ, Oncologist, 1/1/2010
• The management of hepatocellular carcinoma  
  Cabrera R, Nelson DR, Aliment Pharmacol Ther, 1/1/2010
• Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid  
  Levy C, Peter JA, Nelson DR, et al, Aliment Pharmacol Ther, 1/1/2010
• Transfusion has no effect on recurrence in hepatitis C after liver transplantation  
  Rice MJ, Wendling A, Firpi RJ, Hemming AW, Nelson DR, et al, Acta Anaesthesiol Scand, 1/1/2010
• Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1  
  Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, Grigorescu M, Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E, Subramanian ..., Gastroenterology, 1/1/2010
• Hepatitis C virus modulates human monocyte-derived dendritic cells  
  Eksioglu EA, Bess JR, Zhu H, Xu Y, Dong HJ, Elyar J, Nelson DR, Liu C, J Viral Hepat, 1/1/2010
• Fatigue and sleep quality before and after liver transplantation  
  Rodrigue JR, Nelson DR, Reed AI, Hanto DW, Curry M, Prog in Transplant, 1/1/2010
• Influence of serum and soluble CD25 on regulatory and effector T-cell function in hepatocellular carcinoma  
  Cabrera R, Ararat M, Eksioglu EA, Cao M, Xu Y, Wasserfall C, Atkinson MA, Li C, Nelson DR, Scand J Immunol, 1/1/2010
• Telaprevir for previously treated chronic HCV infection  
  McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al, N Engl J Med, 1/1/2010
• Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25)  
  Cabrera R, Ararat M, Cao M, Xu Y, Wasserfall C, Atkinson M, Liu C, Nelson DR, Dig Dis Sci, 1/1/2010
• Novel interferons for treatment of hepatitis c virus  
  Clark V, Nelson DR, Clin Liver Dis, 1/1/2009
• Join now to see all

Books/Book Chapters

• Pharmacogenomics Applications to Patient Care 
  Chapter: Pharmacokinetics of hepatitis C treatment 
  Kawaguchi-Suzuki M, Nelson DR, Frye RFEditors: JA Johnson.American College of Clinical Pharmacy2015
• Therapy of Digestive Disorders 
  Chapter: Longterm care of the liver transplant recipient 
  Soldevila-Pico C, Nelson DREditors: Michael Wolfe.2006
• Clinicians Companion VI: Experts Perspectives on Contemporary Clinical Issues in Hepatitis C 
  Chapter: Future Drug Development 
  Page 21.0 - 24.0Nelson DREditors: Willis Maddrey.2002
• Clinics In Liver Disease 
  Chapter: The Immunopathogenesis of hepatitis C virus infection 
  Page 931.0 - 953.0Nelson DREditors: Raymond Koff.2001
• The Clinician�s Companion IV: Expert Perspectives on Contemporary Clinical Issues in Hepatitis C 
  Chapter: Host immune response in pathogenesis of hepatitis C 
  Nelson DREditors: LA Cerruto.Projects In Knowledge Inc.2001
• Methods in Molecular Medicine, Vol 19: Hepatitis C Protocols 
  Chapter: Determination of HCV-specific bulk CD8+ activity in liver 
  Nelson DREditors: JYN Lau.Humana Press Inc.1998
• Therapies for Viral Hepatitis 
  Chapter: Pathogenesis of chronic hepatitis C virus infection 
  Nelson DR, Lau JYNEditors: RF Schinazi.International Medical Press1998
• Join now to see all

Abstracts/Posters

• HCV Difficult to treat cases
  Nelson DR, AASLD Postgraduate Course, Washington, 1/1/2017
• Electronic Health Record Consent Panel: Consent2Share
  Nelson DR, American Medical Informatics Association, Washington, 1/1/2017
• Targeting HCV: What have we learned from real world roll out of DAAs
  Nelson DR, Canadian Symposium on HCV, Montreal, 1/1/2016
• Patient oriented research funding opportunities
  Nelson DR, AASLD Clinical Research Workshop, Boston, 1/1/2016
• HCV-TARGET: Transforming phase 4 research in hepatitis C and other therapeutic areas
  Nelson DR, US FDA- CDERCASE, Washington, 1/1/2016
• Hepatitis C: How to provide the best treatment with what I have
  Nelson DR, Paris Hepatitis Conference, Paris, 1/1/2016
• Real world impact of DAA regimens
  Nelson DR, Hong Kong Association for Study of Liver Disease, Hong Kong, 1/1/2015
• Impact of viral eradication on morbidity/mortality
  Nelson DR, Hong Kong Association for Study of Liver Disease, Hong Kong, 1/1/2015
• Viral Hepatitis
  Nelson DR, Grand Rounds, University of Pennsylvania, Philadelphia, 1/1/2015
• Hepatitis C: Emerging Treatment Paradigms
  Nelson DR, American College of Gastroenterology Regional Postgraduate Course, Ft Myers, 1/1/2014
• Hepatology Highlights of 2013
  Nelson DR, American College of Gastroenterology Regional Postgraduate Course, Ft Myers, 1/1/2014
• Real world experience with DAA regimens
  Nelson DR, AASLD/EASL Special Conference on Hepatitis C, NYC, 1/1/2014
• Infected with HCV Genotype 3: ALLY-3 Phase 3 Study
  Nelson DR, AASLD, Boston, 1/1/2014
• All-oral 12-week Combination Treatment With Daclatasvir and Sofosbuvir in Patients
  Nelson DR, AASLD, Boston, 1/1/2014
• HCV therapies in Treatment Experienced
  Nelson DR, Viral Hepatitis Conference, Frankfurt, 1/1/2014
• Changing Treatment Paradigms for HCV
  Nelson DR, American College of Gastroenterology Postgraduate Course, San Diego, 1/1/2013
• The New Era of HCV Therapies : IFN-free regimens
  Nelson DR, The Viral Hepatitis Congress, Frankfurt, 1/1/2013
• Evolving treatment paradigms for hepatitis C
  Nelson DR, Wu Lieping Medical Foundation Meeting, Beijing, 1/1/2013
• HCV Treatment in Special Populations
  Nelson DR, Israeli Gastroenterology Society Meeting, Eilot, Isreal, 1/1/2013
• Real World Data on HCV Patients Treated with Protease Inhibitors
  Nelson DR, Israeli Gastroenterology Society Meeting, Eilot, Isreal, 1/1/2013
• HCV-TARGET
  Nelson DR, FDA Research Meeting, Silver Springs, 1/1/2013
• Overviews of therapies in development: Interferon-free regimens
  Nelson DR, The Viral Hepatitis Congress, Frankfurt, 1/1/2012
• Nucleoside/nucleotide analogues
  Nelson DR, EASL/AASLD Special Conference, Prague, 1/1/2012
• Hepatitis Single Topic Symposium: Classes and Mechanisms of DAAs
  Nelson DR, American Association for the Study of Liver Disease, Emory, 1/1/2012
• Advances of diagnosis and treatment of HCV in US
  Nelson DR, National Conference of the Severe and Complicated Liver Diseases, China, 1/1/2011
• Join now to see all

Lectures

• High SVR12 with 16 Weeks of Tegobuvir and GS-9256 plus Peginterferon-alfa 2a and Ribavirin in Treatment-Naive Genotype 1 HCV Patients 
  Barcelona - 1/1/2012
• Hans Fromm Memorial Lecture: Hepatitis C 
  Hanover - 1/1/2011
• The treatment of hepatitis c infection: present and future 
  New Orleans - 1/1/2010
• Phase 2 Studies with Albinterferon Alfa-2b dosed q4wk provide Insights into Dose Selection For Future Studies 
  Lahaina, Hawaii - 1/1/2007
• Join now to see all

Other

• Improving the Standard of Care for HCV Management: Available and Emerging Strategies for Optimal Patient Outcomes 
  Nelson DR, PeerView CME Activity
  www.peerviewpress.com/n207
  1/1/2009